A novel phenotype-based drug-induced liver injury causality assessment tool (DILI-CAT) allows for signal confirmation in early drug development

Richard P. Hermann¹ | Don C. Rockey² | Ayako Suzuki³,⁴ | Michael Merz⁵ | Hans L. Tillmann⁶,⁷

Summary

Background: Drug-induced liver injury (DILI) requires accurate case adjudication, with expert opinion being the current best practice.

Aim: We utilised a novel DILI causality assessment tool (DILI-CAT), which uses drugspecific liver injury phenotypes, to examine potential DILI in early phase ximelagatran clinical development.

Methods: We conducted a retrospective analysis of liver injury events from four Stroke Prevention using an ORal Thrombin Inhibitor in Atrial Fibrillation (SPORTIF) trials, in which patients were randomised to receive oral ximelagatran or adjusted-dose warfarin. A stepwise process was used with iterative adjustments. The DILI phenotype was characterised by latency, R-value, and AST/ALT ratio. A scoring algorithm was applied to liver events to assess how closely the liver events matched the Interquatile-Range for the working phenotype for each of the three parameters.

Findings: Data from 3115 patients included in the SPORTIF trials as above were available. The initial ximelagatran phenotype was developed based on five liver injury cases from the ximelagatran arm and was then validated against an additional eight cases (5 ximelagatran, 3 warfarin); in these eight cases, there was a statistically significant difference in the total DILI-CAT scores of the two drugs (p = 0.016) between ximelagatran and warfarin. Together, these ten ximelagatran cases generated a second, refined ximelagatran phenotype, which was validated against an additional 75 cases (53 ximelagatran/22 warfarin)—again with statistically significant different DILI-CAT ximelagatran vs. warfarin scores (p < 0.001).

Conclusion: DILI-CAT, a clinically intuitive, data-driven, computer-assisted scoring algorithm, is a useful tool for early detection of drug’s hepatotoxicity in clinical drug development.
1 | INTRODUCTION

Drug-induced liver injury (DILI) is a serious safety concern during drug development. A critical issue in DILI diagnosis is its accurate adjudication. A number of quantitative and semi-quantitative assessment tools have been developed. The most widely used tool, the Roussel Uclaf Causality Assessment Method (RUCAM), has been in use for almost three decades; however, this tool and the other tools do not consider a drug’s signature (also known as a drug’s phenotypes) characteristic for a specific drug. This point is emphasised by the fact that expert opinion, which by its nature is likely to incorporate drug phenotypes into the adjudication process, appears to be superior to RUCAM in DILI adjudication. Experts likely intuitively take into account drugs’ DILI phenotypes in adjudication process even when no formalised phenotype has been developed. Therefore, many experts recommend expert opinion as the optimal adjudication process.

Here, we hypothesised that a DILI causality assessment tool (DILI-CAT), as described earlier, can be used to help clinically determine the causality of DILI throughout a clinical development programme, starting in the early phases, by recognition of drug-specific phenotypes and application of a data-driven scoring algorithm to enhance the detection of liver signals and their adjudication during the drug development process.

In 2006, after reports of hepatotoxicity, the US Food and Drug Administration (FDA) halted clinical development of ximelagatran, an oral direct thrombin inhibitor designed for the prevention or treatment of thromboembolic conditions, due to concerns about DILI. Therefore, we have taken advantage of the extensive data set available from this programme to explore the possibility that the DILI-CAT could identify a drug-specific DILI signature early in development. Using ximelagatran clinical trial data, we describe the clinical signature of ximelagatran-associated liver injury with an aim to optimise accurate signal detection of true ‘liver signals’ using the DILI-CAT.

2 | METHODS

2.1 | Data source

Patients enrolled in the four Stroke Prevention using an ORal Thrombin Inhibitor in Atrial Fibrillation (SPORTIF) trials had a diagnosis of atrial fibrillation and had a planned treatment duration of >35 days. All four trials randomised patients to receive oral ximelagatran or adjusted-dose warfarin. The phase 2 trials included SPORTIF 2 and SPORTIF 4, and the phase 3 trials included SPORTIF 3 (open-label) and SPORTIF 5 (double-blind). All the data were provided by AstraZeneca (AZ) data management at the same time. Due to file size, SPORTIF 3 was electronically transferred in 18 subsets. We analysed the data starting with the phase 2 studies and then progressed to phase 3 data to mimic the accrual of cases from a clinical development programme.

Key Points

- Currently available drug-induced liver injury (DILI) adjudication scoring systems treat all drugs similarly.
- We utilised a novel data-driven computerised algorithmic causality tool known as DILI-CAT (DILI causality assessment tool), which aims to characterise a specific DILI phenotype for specific drugs—in this case using ximelagatran as an example.
- This approach clearly led to identification of a DILI signal for ximelagatran, and theoretically could have been used during early drug development to highlight ximelagatran’s potential hepatotoxicity phenotype.

Records of subjects who were enrolled in countries that did not allow reuse of the trial data were excluded from the data set for regulatory concerns. Records of subjects who failed screening or withdrew consent during the trials were also excluded.

Data were fully de-identified, and this study was declared to be non-human subject research by the East Carolina University Institutional Review Board.

2.2 | Parameters used for DILI-CAT phenotyping

Liver injury events were defined in line with FDA’s guidance for drug development as: (a) alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥3 times (*) the upper limit of normal (ULN) or (b) alkaline phosphatase (ALP) or bilirubin ≥2*ULN. Three parameters were evaluated. The first parameter was latency, defined in days as the time between the start of the drug and time ALT or AST reached 3 × ULN or ALP reached 2 × ULN. The other two parameters reflect liver injury pattern, specifically R-values were computed at the time ALT or AST reached 3 ULN or ALP reached 2 ULN using the well-established formula. The other two parameters reflect liver injury pattern, specifically R-values were computed at the time ALT or AST reached 3 ULN or ALP reached 2 ULN using the well-established formula, ratio between "ALT in ULN" / "ALP in ULN" and AST/ALT ratio (de Ritis ratio) at onset of liver injury.

2.3 | Point allocation

Point allocations were chosen using our best judgement to assign points based on the importance of the variables used in the DILI-CAT. A full (100%) points were given in value for respective parameter when values of the specific case fell within the Interquartile range (IQR). Only half (50%) of the points available were given when values fell in the 15th-25th or 75th-85th percentile, and only 25% of the points available were given for values in the 10th-15th or 85th-90th percentile. Zero points were given when values fell in the 0th-10th or 90th-100th percentile. Points were deducted when values fell outside the range of the identified phenotype (a 25% reduction
in points). If a value was both outside the range and an outlier, there was a 50% deduction in points (Table 2). Outliers were defined using a modified approach and described in supplement (Material S1).

2.4 | Steps for phenotyping and validating the ximelagatran-associated liver enzyme elevation

The fundamentals of the DILI-CAT approach are presented in abstract and manuscript that have been published in a preliminary form.8,9 In this setting of using DILI-CAT to reflect a drug development process, a stepwise approach was used, as in drug development, not all cases are available immediately.

In Step 1 (Table 1, see Figure S1 for a visual explanation), we identified a preliminary ximelagatran DILI-CAT phenotype using liver injury cases from the SPORTIF 2 clinical trial. The phenotype was developed based on the values for latency, R-value and AST/ALT ratio from cases reaching AST or ALT 3×ULN or AlkPhos 2×ULN. For each parameter (latency, R-value and AST/ALT ratio), we calculated median, interquartile range (IQR), percentile steps (0–10, 10–15 and 15–25 on either side of the IQR), and range as well as outlier values.

In Step 2, we assessed phenotype validity by comparing ximelagatran to warfarin cases. This was done by generating a score for each case using a scoring algorithm (Table 2). This algorithm was based on how closely cases matched the IQR for the working phenotype (Figure 1).

Step 3: The cumulative ximelagatran cases with elevated liver values from both data sets were then combined to develop a refined DILI-CAT phenotype (repeat Step 1).

Step 4: Then we repeated Step 2, which involved testing additional cases, again using the DILI-CAT scoring algorithm from the next even larger data set against the new refined phenotype. The concept is that these steps can be repeated as often as additional cases accrue from the trials in the clinical development programme, thereby leading to an ever more refined drug DILI-CAT phenotype along drug development.

2.5 | DILI-CAT scoring analysis and interpretation for ximelagatran-associated liver enzyme elevation

For each analysis, the parameter with the greatest statistical difference between ximelagatran and warfarin using Mantel-Haenszel rank sum test was considered to be the most important clinical feature distinguishing the two drugs and was therefore ‘weighted’ such that it could receive double the points of the other parameters—that is a maximum of 40 points (Table 2). The remaining two parameters could receive a maximum of 20 points. It was decided, a priori, that if there was no statistically significant difference among any of the parameters or no comparison data were available, latency would be used as the default ‘weighted’ parameter since time to onset of liver injury is typically an important element in the determination of DILI causality.1–3,17,18

2.6 | Statistical analysis

The nonparametric Mann-Whitney rank test was used to compare the ximelagatran phenotype to the warfarin phenotype for each of the three parameters, where a U-value of zero indicated lack of overlap—that is values from one drug are either all lower

### TABLE 1  DILI-CAT step sequence, ximelagatran phenotype

| Early phase trials | Late phase trials |
|--------------------|------------------|
| Step | Action | Data Source | Number of Elevated LFT Cases |
| | | (n ximelagatran subjects / n warfarin subjects) | |
| Step 1 | **Develop** preliminary drug phenotype using DILI-CAT phenotyping | SPORTIF 2 (86/30) | 5/0 |
| Step 2 | **Validate** preliminary phenotype using additional cases with DILI-CAT scoring algorithm | SPORTIF 3 subset 1* (86/105) | 5/3 |
| Step 3 (repeat Step 1) | **Develop** refined drug phenotype using DILI-CAT phenotyping | SPORTIF 2 (86/30) plus SPORTIF 3 subset 1* (86/105) = 172/135 | 10/3 |
| Step 4 (repeat Step 2) | **Validate** refined phenotype using additional cases with DILI-CAT scoring algorithm | SPORTIF 3 remaining cases (1014/1010) plus SPORTIF 5 (329/323) = 1343/1333 | 53/22 |
| Repeat Step 1 and Step 2 with new cases to further refine phenotype | **Develop** next refined phenotype, then **Validate** with the new cases as they accrue | *n* number of additional studies | *n* number of new cases |

* Out of a total of 18 subsets.

**Abbreviations:** DILI-CAT, drug-induced liver injury causality assessment tool; LFT, liver function test; SPORTIF, Stroke Prevention using an ORal Thrombin Inhibitor in Atrial Fibrillation.

*n* reflective of number of additional cases becoming available.

*Out of a total of 18 subsets.
or all higher than the comparator. To assess the ability of the DILI-CAT-derived ximelagatran phenotype for differentiating liver injury events occurring during ximelagatran versus warfarin treatment, their respective DILI-CAT scores were tested for significance of difference using the Mantel-Haenszel test for trend, that considers the magnitude of ordinal values and therefore can be more powerful for numerical values compared to chi-square. In the event that two or more parameters had the same p value (using three decimal points), the U value was used to identify the most significant p value. Data handling was done using Microsoft Excel, and IBM SPSS version 25 was used for statistical analysis.

3 | RESULTS

3.1 | Clinical characteristics of the study populations

Because of the rigorous de-identification process, basic demographic information such as age and race were not available. Data from 3115 out of 8415 subjects were available for analysis (Figure 2). Previous work by Lee et al, revealed that the same SPORTIF patient population had a mean duration of treatment with ximelagatran of 480 days and that the incidence of ALT >3 ULN was 7.9% in the ximelagatran group versus 1.2% in the comparator group. SPORTIF 2 treatment duration was limited to less than 90 days, while in the other SPORTIF studies treatments were extended to 3 years.

3.2 | Step 1. Preliminary DILI-CAT phenotyping for ximelagatran

The first data set was the phase 2 SPORTIF 2 trial with 116 subjects (86 on ximelagatran and 30 on warfarin). We identified five (9.3%) patients with liver injury in the ximelagatran arm and no patients with liver injury in the warfarin arm. All of the ximelagatran liver events occurred at visits six and seven, translating into a median latency of 69 days (IQR 58–78 days, Table 3). The median R-value was 8.7 (IQR 5.93–12.72), indicating hepatocellular injury, and the median AST/ALT ratio was 0.61 (IQR 0.60–0.65; Table 3).

3.3 | Step 2. Validating the preliminary DILI-CAT ximelagatran phenotype

Since we found no liver injury cases in the second small phase 2 data set (SPORTIF 4) to validate our preliminary DILI-CAT ximelagatran phenotype, we used one subset (out of a total 18 subsets) from the phase 3 SPORTIF 3 study. This data set of 191 subjects (86 on ximelagatran and 105 on warfarin) included eight patients with liver injury with five (5.8%) in the ximelagatran arm and three (2.9%) in the warfarin arm, this difference is not significant in chi-squared test ($p = 0.3$).

However, using the DILI-CAT concept, there was a statistically significant difference in the AST/ALT ratio among the groups ($p = 0.025$ Table 4), though R-value ($p = 0.18$) and latency ($p = 0.764$) were not significantly different for the 2 drugs (Tables 4 and 5). Thus, the DILI-CAT-S's were calculated for individual cases with the AST/ALT ratio being the weighted parameter (ie double points for AST/ALT ratio ) since it showed the greatest difference among the parameters.

Applying the DILI-CAT scoring algorithm with phenotype derived from SPORTIF 2 to the SPORTIF 3 subset 1 cases demonstrated no significant difference in any single parameter alone using the individual DILI-CAT scores (Latency $p = 0.46$, R-value $p = 0.13$, and AST/ALT ratio $p = 0.069$). However, when using the total DILI-CAT-S, the ximelagatran and warfarin cases were found to have significantly different clinical features ($p = 0.016$).

3.4 | Step 3—Refining the ximelagatran DILI-CAT phenotype

Next, we refined the ximelagatran phenotype by combining the original five cases of ximelagatran-associated liver injury from SPORTIF 2 with the additional five cases from SPORTIF 3 subset 1 (for a total of 10 ximelagatran-associated cases) to arrive at a refined DILI-CAT ximelagatran phenotype referred to here as the ximelagatran phenotype version 2 (Table 6).

3.5 | Step 4—validation of the ximelagatran phenotype version 2 (XPv2)

Next we applied the refined phenotype XPv2 to assess the remaining phase 3 data (subsets 2-18 from Sportif 3 and all cases from Sportif 3). A total of 2676 subjects (1343 on ximelagatran and 1333 on warfarin) made up the remaining SPORTIF 3 (17 subsets) plus the SPORTIF 5 data set. There were an additional 75 cases of liver injury including 53 (3.9%) ximelagatran cases and 22 (1.7%) warfarin cases ($p < 0.001$). Applying the DILI-CAT scoring algorithm to these 75 cases (see Table S1) and comparing the results to the XPv2 demonstrated that ximelagatran cases differ and show overall statistically significantly higher DILI-CAT-S’s ($p < 0.001$ for AST/ALT score, $p = 0.001$ for latency and R-value scores; Table 7, Figure 3).

3.6 | Iterative refining of the phenotype

A third and final iteration of re-refined phenotype resulted from combining all of the cases from the entire SPORTIF data set to develop the most updated refined ximelagatran phenotype (XPv3). This included 73 cases of liver injury in the ximelagatran arms and 28 cases in the warfarin arms (Table 8).
This study provides compelling evidence that the DILI-CAT offers an objective, accessible and reproducible approach to mitigate some of the inter- and intra-rater variability of DILI causality assessment. Underpinned by clinical knowledge and experience, DILI-CAT defines a drug’s phenotype by allotting points based on a defined computer-assisted yet straightforward algorithm instead of a manual instrument where human interpretation can lead to variation in scores. DILI-CAT fills the need for a computer-assisted method for DILI causality assessment as previously suggested.

Of note, this model was highly predictive even in the absence of formal adjudication results of the cases; and where most of the severe cases of DILI fulfilling Hy’s Law criteria (ie ALT or AST ≥3× ULN and total bilirubin >2× ULN) had been removed from the database available for our analysis due to privacy concerns. However, these adjudication data have been presented previously by Lee et al, which included some patient-level data in their paper on 42 patients with or without an alternative identifiable cause for liver injury. Thirty-seven of those 42 (88%) patients were exposed to ximelagatran. Nineteen of the 37 (51%) had alternative diagnoses for elevated liver enzymes, while 18 out of the 37 (49%) had no alternative diagnosis other than DILI. R-value and AST/ALT ratio were unavailable for the cases, but latency was published. We analysed this latency data using the DILI-CAT scoring algorithm by (a) presence or absence of an alternative diagnosis for patients on ximelagatran and (b) treatment group

### TABLE 2  DILI-CAT scoring algorithm

| Within | Percentage of points per parameter | Final score for the standard parameters | Final score for the "weighted" parameter |
|--------|-----------------------------------|----------------------------------------|----------------------------------------|
| IQR (25th–75th percentile) | 100 | 20 | 40 |
| 25th–15th percentile | 50 | 10 | 20 |
| 75th–85th percentile | 25 | 5 | 10 |
| 15th–10th percentile | 0 | 0 | 0 |
| 85th–90th percentile | 0 | 0 | 0 |
| 10th percentile to minimum of IQR | 0 | 0 | 0 |
| 90th percentile to maximum of range | 0 | 0 | 0 |
| Above/below upper/lower range bounds\(^a\) | -25 | -5 | -10 |
| Outlier\(^a\) | -25% | -10 | -10 |

Abbreviations: DILI-CAT, drug-induced liver injury causality assessment tool; IQR, interquartile range.

\(^a\) If a value is both outside the range and an outlier, −50% is used.

![DILI-CAT Scoring Algorithm Based on Distance from Interquartile Range (IQR)](image)

**FIGURE 1** DILI-CAT scoring algorithm based on distance from interquartile range (IQR). Outliers definition: Values above IQR by 150% of the IQR width or below IQR by 75% of IQR width. Outliers get scored as minus 25%. If value is outside the range and an outlier, then it is scored minus 50%. DILI-CAT, drug-induced liver injury causality assessment tool

### 4 | DISCUSSION

This study provides compelling evidence that the DILI-CAT offers an objective, accessible and reproducible approach to mitigate some of the inter- and intra-rater variability of DILI causality assessment. Underpinned by clinical knowledge and experience, DILI-CAT defines a drug’s phenotype by allotting points based on a defined computer-assisted yet straightforward algorithm instead of a manual instrument where human interpretation can lead to variation in scores. DILI-CAT fills the need for a computer-assisted method for DILI causality assessment as previously suggested.

Of note, this model was highly predictive even in the absence of formal adjudication results of the cases; and where most of the severe cases of DILI fulfilling Hy’s Law criteria (ie ALT or AST ≥3× ULN and total bilirubin >2× ULN) had been removed from the database available for our analysis due to privacy concerns. However, these adjudication data have been presented previously by Lee et al, which included some patient-level data in their paper on 42 patients with or without an alternative identifiable cause for liver injury. Thirty-seven of those 42 (88%) patients were exposed to ximelagatran. Nineteen of the 37 (51%) had alternative diagnoses for elevated liver enzymes, while 18 out of the 37 (49%) had no alternative diagnosis other than DILI. R-value and AST/ALT ratio were unavailable for the cases, but latency was published. We analysed this latency data using the DILI-CAT scoring algorithm by (a) presence or absence of an alternative diagnosis for patients on ximelagatran and (b) treatment group
Figure 2  Data available for analysis, SPORTIF, stroke prevention using an ORal thrombin inhibitor in atrial fibrillation

Table 3  Preliminary DILI-CAT phenotype of ximelagatran based on five cases identified in SPORTIF 2 which was limited to 90 day treatment. (a) shows individual data, (b) shows the median, IQR, percentile, range and outlier values

| Patient ID                  | Day of therapy | $R$-value | AST/ALT ratio |
|-----------------------------|---------------|-----------|---------------|
| (a) Individual data from cases with elevated liver enzymes from SPORTIF 2 |               |           |               |
| Ximelagatran case 2.1      | 69            | 12.7      | 0.49          |
| Ximelagatran case 2.2      | 83            | 8.7       | 0.65          |
| Ximelagatran case 2.3      | 56            | 5.9       | 0.61          |
| Ximelagatran case 2.4      | 58            | 5.8       | 0.6           |
| Ximelagatran case 2.5      | 75            | 13.9      | 0.69          |
|                            | Latency (days)| $R$-value| AST/ALT ratio |
| (b) Statistics for cases with elevated liver enzymes from SPORTIF 2 |               |           |               |
| Median                     | 69            | 8.68      | 0.61          |
| IQR low                    | 58            | 5.93      | 0.6           |
| IQR high                   | 75            | 12.72     | 0.65          |
| 15th–25th percentile       | 57.2          | 5.86      | 0.56          |
| 75th–85th percentile       | 78.2          | 13.12     | 0.67          |
| 10th–15th percentile       | 56.8          | 5.82      | 0.53          |
| 85th–90th percentile       | 79.8          | 13.4      | 0.67          |
| Outlier low                | 45.3          | 0.84      | 0.53          |
| Outlier high               | 100.5         | 22.9      | 0.73          |
| Range                      | 56–83         | 5.75–13.85| 0.49–0.69     |

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; DILI-CAT, drug-induced liver injury causality assessment tool; IQR, interquartile range.
HERMANN E t Al.

For cases without an alternative diagnosis (Figure S2). For subjects on ximelagatran, results showed a statistically significant difference in liver injury cases when comparing those with versus those without an alternative diagnosis ($p = 0.013$).

No significant difference was found between those with liver injury on ximelagatran without alternative diagnosis versus those not on ximelagatran ($p = 0.073$), although nominally it approached statistical significance, despite the small number not on Ximelagatran ($n = 5$).

It is possible that the DILI-CAT score generated is unable to differentiate clinical features of two or more drugs. For instance, when comparing two specific drugs, it is possible that the DILI phenotype for both drugs is so similar that it would require many more cases to detect a difference (assuming a difference exists). It could also be that one of the two drugs has such a wide range of variability for one of the parameters that it creates an overlapping phenotype with the other drug. In case of concomitantly administered medications, drugs that have a synergistic or an additive effect, and are therefore co-dependent, would make the combination signature different from the monotherapy signature. This latter possibility would theoretically allow exploration of different

| Treatment arm             | Latency | R-value | AST/ALT ratio | Latency Score | R-value score | AST/ALT ratio score | Total score (AST/ALT ratio weighted) |
|---------------------------|---------|---------|---------------|---------------|---------------|---------------------|-------------------------------------|
| Ximelagatran case 1       | 43      | 3.32    | 0.64          | -10           | -5            | 20 (40)             | 25                                  |
| Ximelagatran case 2       | 46      | 6.63    | 0.68          | -5            | 20            | 0 (0)               | 15                                  |
| Ximelagatran case 3       | 92      | 7.26    | 0.59          | -5            | 20            | 10 (20)             | 35                                  |
| Ximelagatran case 4       | 427     | 9.41    | 0.47          | -10           | 20            | -10 (-20)           | -10                                 |
| Ximelagatran Case 5       | 45      | 0.56    | 0.65          | -10           | -10           | 20 (40)             | 20                                  |
| Warfarin case 1           | 43      | 2.07    | 1.11          | -10           | -5            | -10 (-20)           | -35                                 |
| Warfarin case 2           | 187     | 2.82    | 0.97          | -10           | -5            | -10 (-20)           | -35                                 |
| Warfarin case 3           | 266     | 0.67    | 1.09          | -10           | -5            | -10 (-20)           | -40                                 |

Note: Dark green = values fitting within the IQR of the phenotype. Light green = light green indicates values that are between the 10th and 25th or between the 75th and 90th percentile. White = values outside of IQR, but still within the range. Light red = outside of range but not outlier. Red = outside of range AND outlier.

Table 4: DILI-CAT scores for SPORTIF 3 (subset 1) cases using the preliminary DILI-CAT ximelagatran phenotype (derived from SPORTIF 2)

Table 5: Summary statistics for DILI-CAT scores for SPORTIF 3 (subset 1) using the preliminary DILI-CAT ximelagatran phenotype (derived from SPORTIF 2)
phenotype profiles for monotherapy versus combination drug regimens.

Given the high cost of drug development and, more importantly, the potential risk to patients, clinical research must be able to detect potential hepatotoxicity as early and as reliably as possible in the drug development process. The best practice for hepatotoxicity causality assessment remains expert opinion. Unfortunately, while robust, it is not practical to attain expert opinion for every case of liver injury in routine clinical practice. Ximelagatran was granted marketing approval in several countries, the US FDA did not grant approval because, in part, of concerns over potential hepatotoxic effects of the drug suggested by elevations of alanine aminotransferase. Indeed, Southworth et al in 2014 published results of a post hoc analysis of the SPORTIF studies using extreme value modelling and found evidence of a liver signal in the phase 2 data, concluding that development could have been halted before further phase 3 development if such statistical methodology had been available at that time. This would have been further strengthened by additional adjudication support tool such as DILI-CAT.

We recognise limitations of this study. First, limited patient level data were available from the SPORTIF programmes. However, the data captured were carefully curated, and complete liver tests along with other critical variables, including timing of the drug and injury, were available. Additionally, the DILI-CAT version presented here does not incorporate potentially important clinical elements such as concomitant medications. Hence, drug-drug and drug-host interaction cannot be fully assessed; this could be important since it is possible that underlying NAFLD may increase the risk for DILI, and female gender may be associated with a hepatocellular presentation of DILI. Nonetheless, further study is required to better understand whether host factors alter the drug-specific phenotypes. Also, data on comorbidities, especially those leading to hepatic

### TABLE 6 Ximelagatran phenotype version 2 (SPORTIF 2 plus SPORTIF 3, subset 1)

| Latency (days) | R-value | AST/ALT ratio |
|---------------|---------|--------------|
| Median        | 6.5     | 6.95         | 0.625       |
| IQR low       | 45.75   | 5.14         | 0.565       |
| IQR high      | 85.25   | 10.24        | 0.658       |
| 15th–25th percentile | 44.3    | 2.35         | 0.483       |
| 75th–85th percentile | 209.25  | 13.12        | 0.684       |
| 10th–15th percentile | 43.2    | 0.84         | 0.472       |
| 85th–90th percentile | 393.5   | 13.74        | 0.689       |
| Outlier low   | 16.125  | 1.32         | 0.496       |
| Outlier high  | 144.5   | 17.88        | 0.796       |
| Range         | 43–427  | 0.56–18.85   | 0.47–0.69   |

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; IQR, interquartile range; SPORTIF, Stroke Prevention using an ORal Thrombin Inhibitor in Atrial Fibrillation.

### TABLE 7 DILI-CAT scoring algorithm applied to the remaining SPORTIF 3 (subsets 2–18) plus SPORTIF 5 cases using the XPv2 (derived from SPORTIF 2 plus SPORTIF 3 subset 1)

| Treatment                  | Latency | R-value | AST/ALT ratio | Latency score | R-value score | AST/ALT score | Total score (AST/ALT ratio weighted) |
|----------------------------|---------|---------|---------------|--------------|--------------|---------------|--------------------------------------|
| **Statistics for original values** |         |         |               |              |              |               |                                      |
| Ximelagatran (n = 53) median | 88      | 4.43    | 0.65          | NA           | NA           | NA            | NA                                   |
| Warfarin (n = 22) median    | 155     | 1.05    | 1.136         | NA           | NA           | NA            | NA                                   |
| Mann–Whitney U value        | 328     | 351     | 310<sup>a</sup> | NA           | NA           | NA            | NA                                   |
| Mann–Whitney rank test P-value | 0.003   | 0.007   | 0.001<sup>a</sup> | NA           | NA           | NA            | NA                                   |
| **Statistics for distance from IQR and for DILI-CAT** |         |         |               |              |              |               |                                      |
| Ximelagatran (n = 53) median distance from IQR | 2.75     | 0.81    | 0.065         | 0            | 0            | 0 (0)<sup>a</sup> | 20                                   |
| Warfarin (n = 22) median distance from IQR | 69.75   | 4.09    | 0.478         | 0            | 0            | -10 (-20)<sup>a</sup> | -20                                  |
| Mann–Whitney U for distance from IQR | 252     | 350     | 199.5<sup>a</sup> | 286           | 350.5        | 211.5         | 181                                  |
| Mann–Whitney test for distance from IQR P-value | <0.001     | 0.004   | <0.001        | <0.001       | 0.004        | <0.001         | <0.001                               |
| DILI-CAT assessed by Mantel-Haenszel test for trend | NA      | NA      | NA            | 0.001<sup>c</sup> | 0.001<sup>c</sup> | <0.001<sup>c</sup> | <0.001<sup>c</sup> |

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; DILI-CAT, drug-induced liver injury causality assessment tool; IQR, interquartile range; NA, not applicable; SPORTIF, Stroke Prevention using an ORal Thrombin Inhibitor in Atrial Fibrillation; XPv2, ximelagatran phenotype version 2.

<sup>a</sup>Lowest U value, therefore most significant.

<sup>b</sup>Significant differences in Mann–Whitney test for distance, and for the most marked difference defined by lowest Mann–Whitney U value; the darker grey shaded area indicates the Mann–Whitney test for statistical differences.

<sup>c</sup>Significant differences in Mantel-Henszel Test.
impairment, are not captured in this model. However, these factors are somewhat mitigated by the routine process of screening study subjects with established inclusion and exclusion criteria. This results in a general effect of decreasing heterogeneity. Theoretically, the more homogeneous the population, the more similar one might expect the patterns to be for latency and biochemical features in bona fide DILI cases due to the implicated drug. De-challenge and re-challenge timing data may also improve the predictive ability of this method. Unfortunately, such data are often not accurately and consistently captured in clinical trial or real-world settings. In this study, the de-challenge parameter was not included since complete information was not always available in the data set. Finally, given that the premise of DILI-CAT is based on fundamental clinical criteria such as time to onset (ie latency) and biomarkers of pathophysiology (ie biochemical features analogous to R-value and AST/ALT ratio), the door is open for further exploration into applying these same principles to other organ-specific drug-induced adverse events. These would include other gastrointestinal, dermatologic, renal, cardiac, haematologic or central nervous system adverse events, to name a few. Ideally, any identified case of concern would also be confirmed in in vitro assays as monocytes derived hepatocyte like cells. In a number of studies, this test has shown promise as a confirmatory study.

In addition, the most severe cases of DILI were not available for this study due to data privacy concerns. However, if they had been available, this data conceivably would have improved the discrimination potential of the DILI-CAT. Any potential effects of age or race on this model remain unknown as these variables were removed in order to anonymise the data, but they could offer opportunities for further research and refinement of this causality assessment methodology.

In conclusion, we have presented a model that may help to detect an early DILI signal by identifying events in relation to a clinical phenotype (timing and biochemical pattern). Although formal reproducibility and validity testing has not yet been performed, this analysis suggests that the DILI-CAT provides a consistent and efficient way to distinguish between cases where the drug is responsible for DILI and cases where it is not and may be applicable across different stages of clinical development. In the future, prospective inclusion of an effort to detect (early) DILI events using the DILI-CAT approach may prove to identify DILI signals early and improve overall drug development.

ACKNOWLEDGEMENTS

Editorial assistance, funded by AstraZeneca, was provided by Peloton Advantage, LLC, an OPEN Health company. Additional statistical support was provided by Daniel Chima, an employee of AstraZeneca.

Declaration of personal interests: Richard Hermann is a full-time employee and stockholder at AstraZeneca. Don C. Rockey, Ayaka Suzuki, and Michael Merz have nothing to disclose. Hans L. Tillmann is a stockholder of Abbott, AbbVie and Gilead outside the submitted work. He reports that his wife is a full-time employee of AbbVie. RH is employee of AstraZeneca and holds stock in AstraZeneca, MM is a consultant to AstraZeneca. DCR and AS have no conflict of interest.
AUTHORSHIP
Guarantor of the article: None.

Author contributions: All authors were involved in study concept and design, acquisition of data, interpretation of data, drafting of the manuscript and critical revision of the manuscript for important intellectual content. Hans L. Tillmann and Richard Hermann have verified the underlying data. Hans L. Tillmann carried out data analysis. Richard Hermann carried out project administration and supervision. Don C. Rockey was involved in literature review figures and data analysis.

DATA AVAILABILITY STATEMENT
All data used are own by AstraZeneca, who would need to be contacted for data access.

ORCID
Don C. Rockey https://orcid.org/0000-0002-3751-2961
Hans L. Tillmann https://orcid.org/0000-0003-1401-2208

REFERENCES
1. Danan G, Benichou C. Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993;46:1323-1330.
2. Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci. 2016;17:14.
3. Rockey DC, Seeff LB, Rochon J, et al. US drug-induced liver injury consensus. J Hepatol 2019; 70: 1222 – 61.
4. Regev A, Seef L, Merz M, Ormarsdottir S, Aithal GP, Gallivan J, Watkins PB. Causality assessment for suspected DILI during clinical phases of drug development. Drug Saf 2014; 37Suppl 1Suppl 1(1): S47-56.
5. Hey-Hadavi J, Seekins D, Palmer M, et al. Overview of causality assessment for drug-induced liver injury (DILI) in clinical trials. Drug Saf. 2021;44:619-634.
6. Aithal GP, Watkins PB, Andrade RJ, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011;89:806-815.
7. Tillmann HL, Barnhart HX, Serrano J, Rockey DC. A novel computerized drug-induced liver injury causality assessment tool (DILI-CAT). Hepatology. 2016;64(Suppl 1): A320-A321.
8. Tillmann HL, Suzuki A, Merz M, Hermann R, Rockey DC. Novel computer-assisted drug-induced liver injury causality assessment tool (DILI-CAT). medRxiv March 5, 2021.21252982. 10.1101/2021.03.05.21252982
9. Petersen P, Grind M, Adler J, SPORTIF II Investigators. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study. J Am Coll Cardiol. 2003;41:1445-1451.
10. Petersen P. A two-year follow-up of ximelagatran as an oral anticoagulant for the prevention of stroke in patients with nonvalvular atrial fibrillation [abstract]. Neurology 2002; 58Suppl. 3: A477.
11. Petersen P. Tillmann HL, Barnhart HX, Serrano J, Rockey DC. A novel computerized drug-induced liver injury causality assessment tool (DILI-CAT) allows for signal confirmation in early drug development. Aliment Pharmacol Ther. 2022;55:1028–1037. doi: 10.1111/apt.16836
12. Olsson SB, Executive steering committee on behalf of the SPORTIF III investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet. 2003;362:1691-1698. https://doi.org/10.1016/s0140-6736(03)14841-6
13. SPORTIF executive steering committee for the SPORTIF V investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA. 2005;293:690-698.
14. Email communication from University & Medical Center Institutional Review Board East Carolina University, Wednesday, July 17, 2019 8:34:57 AM.
15. U.S. Department of Health and Human Services; Food and Drug Administration. Guidance for industry. Drug-induced liver injury. Premarking Clinical Evaluation. https://www.fda.gov/media/116737/download. Accessed January 30, 2022.
16. de Ritis F, Colorti M, Giusti G. An enzymic test for the diagnosis of viral hepatitis; the transaminase serum activities. Clin Chim Acta. 1957:2:70-74.
17. Fontana RJ, Seeff LB, Andrade RJ. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology. 2010;52:730-742.
18. Rochon J, Protiva P, Seeff L, et al. Reliability of the Roussel Uclaf causality assessment method for assessing causality in drug-induced liver injury. Hepatology. 2008;48:1175-1183.
19. Lee WM, Larrey D, Olsson R, et al. Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf. 2005;28:351-370.
20. Wouters OJ, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market, 2009-2018. JAMA. 2020;323:844-853.
21. Southworth H. Predicting potential liver toxicity from phase 2 data: a case study with ximelagatran. Stat Med. 2014;33:2914-2923.
22. Tarantino G, Conca P, Basile V, et al. A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease. Hepat Res. 2007;3:410-415.
23. Suzuki A, Barnhart H, Gu J, et al. Associations of gender and a proxy of female menopausal status with histological features of drug-induced liver injury. Liver Int. 2017;37:1723-1730.
24. Benesic A, Rotter I, Drugi D, et al. Development and validation of a test to identify drugs that cause idiosyncratic drug-induced liver injury. Clin Gastroenterol Hepatol. 2018;16:1488-94.e5.
25. Gerhardt F, Benesic A, Tillmann HL, et al. Iberogast-induced acute liver failure-Reexposure and in vitro assay support causality. Am J Gastroenterol. 2019;114:1358-1359.
26. Weber S, Wong GLH, Wong VWS, Benesic A, Chan HLY, Gerbes AL. Monocyte-derived hepatocyte-like cell test: a novel tool for in vitro identification of drug-induced liver injury in patients with herbal or dietary supplements. Digestion. 2021;102:650-653. https://www.karger-com.jproxy.lib.ecu.edu/Article/FullText/509391

SUPPORTING INFORMATION
Additional supporting information will be found online in the Supporting Information section.